Targeted Therapy (Antibody-Drug Conjugate)
22 molecules in this therapeutic area. Open any product for its details, or send an inquiry directly.
Targeted Therapy (Antibody-Drug Conjugate) (22)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Loncastuximab Tesirine |
ADC | Hematologic | ||
|
Molecule
Loncastuximab Tesirine
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
||||
Mirvetuximab Soravtansine |
ADC | Solid Tumour | ||
|
Molecule
Mirvetuximab Soravtansine
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Naratuximab Emtansine |
ADC | Hematologic | ||
|
Molecule
Naratuximab Emtansine
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
||||
Patritumab Deruxtecan |
ADC | Solid Tumour | ||
|
Molecule
Patritumab Deruxtecan
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Pivekimab Sunirine |
Anti-CD123 ADC, DNA-alkylating payload | Hematologic | ||
|
Molecule
Pivekimab Sunirine
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
Anti-CD123 ADC, DNA-alkylating payload |
||||
Rovalpituzumab Tesirine |
ADC | Solid Tumour | ||
|
Molecule
Rovalpituzumab Tesirine
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Tafasitamab |
ADC | Hematologic | ||
|
Molecule
Tafasitamab
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
||||
Telisotuzumab Vedotin |
ADC | Solid Tumour | ||
|
Molecule
Telisotuzumab Vedotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Tisotumab Vedotin |
ADC | Solid Tumour | ||
|
Molecule
Tisotumab Vedotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Zilovertamab Vedotin |
ADC | Solid Tumour | ||
|
Molecule
Zilovertamab Vedotin
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
||||
Loncastuximab TesirineTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
|
Mirvetuximab SoravtansineTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
Naratuximab EmtansineTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
|
Patritumab DeruxtecanTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
Pivekimab SunirineTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
Anti-CD123 ADC, DNA-alkylating payload |
|
Rovalpituzumab TesirineTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
TafasitamabTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Hematologic
Drug Class / Mechanism
ADC |
|
Telisotuzumab VedotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
Tisotumab VedotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|
Zilovertamab VedotinTargeted Therapy (Antibody-Drug Conjugate) |
|
|
Therapeutic Category
Targeted Therapy (Antibody-Drug Conjugate)
Oncology Type
Solid Tumour
Drug Class / Mechanism
ADC |
|